Viewing Study NCT01815294

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 1:43 AM
Ignite Modification Date: 2026-02-25 @ 4:48 PM
Study NCT ID: NCT01815294
Status: COMPLETED
Last Update Posted: 2015-12-04
First Post: 2013-03-14
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer
Sponsor: Janssen Research & Development, LLC
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Neoplasms View
None Neoplasms, Ovarian View
None Neoplasms, Breast View
None Advanced or Refractory Solid Malignancies View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Ovarian cancer View
None Breast cancer View
None Solid malignancy View
None Advanced or refractory solid malignancy View
None Metastatic cancer View
None DOXIL/CAELYX View
None Doxorubicin HCL View
None Bioequivalence View